Allergy Territory Account Specialist

What are these roles going to promote? Something new? There's literally 100 positions posted... curious...

 

Remibrutinib

 

Is there a start date and training details?

 

Remibrutinib CSU. No other assets in the allergy portfolio yet.

 

Who is promoting Xolair in food allergy?

 

The same people that have been promoting Xolair since it was launched in 2003....what a dumb ass question.

 

when are interviews starting let’s gooo

 

Yes and yes. If you are selected for a phone screen, you will receive this info.

 

Food allergy was approved recently in 2024, ni competition, would make sense to expand sales force. And by the way Remibrutinib is probably not as safe and effective as Xolair. Good luck to beat the cougar Xolair that has great CAGR after more than 20 years on the market

 

Bring it on future Remi allergy team - we’re waiting for you with boxing gloves on

 

you got a phone screen?? Internal employee??

 

Food allergy is going to be huge. High unmet need.Would make sense to increase effort and investment.

 

Remibrutinib will be 3rd line treatment. Sales forecast will be a challenge.

 

Out-of-stock is the bigger risk. Physicians and patients want the latest stuff and the Ucare people are so excited and will write the fitting guideline.

 

In Europe first Xolair biosimilar will be launched by Celltrion in the next weeks, they are known for creative pricing, if they offer a flat price like they do for Adalimumab the entire NPV calculation for Remibrutinib will colapse

 

Chronic idiopathic urticaria is an unpleasent condition but not life threatening, Will urticaia patients appreciate the long warning list? It seems to be mandatory by the FDA even for next generation, high specific BTK inhibitors of the latest generations. Pirtobrutinib was recently approved with these warnings:

• Infections: Monitor for signs and symptoms of infection, evaluate promptly, and treat.
• Hemorrhage: Monitor for bleeding and manage appropriately.
• Cytopenias: Monitor complete blood counts during treatment.
• Atrial Fibrillation and Atrial Flutter: Monitor for symptoms of arrhythmias and manage appropriately.
• Second Primary Malignancies: Other malignancies have developed, including skin cancers and other carcinomas. Monitor and advise patients to use sun protection.
• Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception.

 

How can you even compare this drug to Remi - it’s for cancer

 

Doesn't matter, the molecular target is the same, cancer dosage might be different, see:

A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications